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PFO ¼ paTo the Editor: Atrial arrhythmias after percutaneous patent foramen
ovale (PFO) closure, including atrial ﬁbrillation (AF), has been
consistently reported in different series suggesting a causal link
between mechanical closure of PFO and the new onset of post-
procedural arrhythmias (1–3). We have systematically assessed the
effect of percutaneous PFO closure upon the development of post-
procedural arrhythmias in 221 consecutive patients (144 women;
mean age 48  13 years) undergoing percutaneous PFO closure. At
clinical evaluation, no patient had symptoms indicative or suggestive
of arrhythmias. Indications for closure were the presence of signiﬁ-
cant (grade >1) basal or Valsalva-induced right-to-left atrial shunt
(RLS) at contrast transthoracic echocardiography (TTE) associated
with cryptogenic stroke (n¼ 75), repeated transient ischemic attacks
(n ¼ 108), severe migraine (4 attacks/monthly resistant to triple
pharmacologic therapy including topiramate) with presence of
multiple bilateral cerebral ischemic lesions at magnetic resonance
imaging (n ¼ 30), decompression illness (n ¼ 4), platypnea-
orthodeoxia syndrome (n ¼ 2), and documented peripheral embo-
lism (n¼ 2). All patients underwent 24-/48-h Holter monitoring or
external loop recorder electrocardiography (ECG) recording 1 to 3
months before PFO closure and between 3 and 6 months after the
procedure. All ECG recordings were manually reviewed. Supra-
ventricular (SV) arrhythmias were categorized as sporadic ectopic
beats (5% of total beats), AF (lasting 30 s), and SV tachycardia.
Contrast TTE was performed at 1 and 6 months to evaluate residual
RLS. To evaluate predictors of post-procedural arrhythmias, a binaryPredictors of Post-Procedural Arrhythmias
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tent formane ovale.logistic regression analysis was performed. The following dichoto-
mized variables were considered as potential risk predictors in
exploratory analysis: age, sex, body mass index, device type, pre-
closure arrhythmias, atrial septal aneurysm and septal excursion,
severity of RLS shunt, and immediate and 6-month residual shunt
(Table 1). Variables included in the multivariable model were those
showing a statistical association (p < 0.1) with post-procedural
arrhythmias at univariate analysis. Data are reported as mean 
SD. A 2-sided p value<0.05 was required for statistical signiﬁcance.
The mean follow up was 14  7.8 months.
Pre-closure SV arrhythmias were detected in 51 patients (23%)
who were all asymptomatic. Transient episodes of AF were
detected in 9 patients (4%); sporadic ectopic beats in 36 patients
(16.3%), and ST in 6 patients (2.7%). Paroxysmal AF represented
18% of all arrhythmias. At 3- to 6-month Holter monitoring, SV
arrhythmias were present in 48 patients (21.7%). Transient
episodes of AF were detected in 11 patients (4.9%), sporadic
ectopic beats in 33 patients (14.9%), and SV tachycardia in 4
patients (1.8%). AF represented 22.9% of all post-procedural
arrhythmias. In synthesis, 29 patients presented SV arrhythmias
before and after PFO closure, 21 patients had arrhythmias only
before PFO closure and 18 patients had arrhythmias only after
PFO closure. All the 9 patients presenting AF before PFO closure
had the same arrhythmia after the procedure. At multivariate
analysis, the only predictor of post-closure arrhythmias was the
presence of pre-closure arrhythmias (p < 0.0001) (Table 1).95% Conﬁdence Interval p Value
0.9–4.4 0.061
0.9–3.4 0.128
0.5–1.7 0.701
0.6–2.2 0.661
1.1–4.2 0.025
0.2–.6.6 0.796
4.5–18.7 <0.001
0.1–4.3 0.533
0.3–3.3 0.956
0.6–1.1 0.682
0.5–1.9 0.941
0.2–2.5 0.585
0.7–1.8 0.637
0.2–1.9 0.452
0.7–3.0 0.290
0.9–4.1 0.100
4.2–17.9 <0.001
PFO occluder (St. Jude Medical, Little Canada, Minnesota); Intrasept
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2450Our study has the unique peculiarity in being speciﬁcally
designed to investigate the effect of percutaneous PFO closure upon
post-procedural atrial arrhythmias. All patients included in the
study underwent 1 to 3 months before closure to rhythm moni-
toring by using traditional 24-/48-h Holter-ECG recording or
external loop recorder monitoring (one-third). ECG recording
has been repeated 3 to 6 months after transcatheter PFO closure,
a time interval considered optimal for the anatomical stabiliza-
tion of the device. The main ﬁnding of our study is that percuta-
neous PFO closure is not per se an inductor for post-procedural
atrial arrhythmias; indeed, the only predictor of post-procedural
arrhythmias appear to be the presence of arrhythmias before PFO
closure. Interestingly, the majority of patients with post-procedural
arrhythmias had the same arrhythmias before PFO closure thus
suggesting an intrinsic increased susceptibility to develop rhythm
disturbances (4). Indeed, at multivariate analysis we could not
identify any predictors of post-procedural arrhythmias except pre-
closure arrhythmias. In particular, residual RLS, device type and
size, atrial and PFO anatomical features were not predictive of post-
procedural arrhythmias. This ﬁnding suggests that the device-
related atrial mechanical stretch per se does not increase electrical
vulnerability in nonsusceptible patients.
An interesting ancillary ﬁnding of this study, albeit non con-
clusive for the lack of a control group, is that the prevalence of
atrial arrhythmias, including atrial ﬁbrillation, in patients with
PFO is unexpectedly higher than that estimated in the general
population (5). This evidence suggests that, at least in a proportion
of patients with PFO, asymptomatic unrecognized arrhythmias
might play a pathogenetic role in systemic embolism. An obvious
ﬂaw of the present study is the technical limitation of the recor-
ding systems used that probably underestimated the true prevalence
of arrhythmias. Furthermore, our study lacks a control group so no
deﬁnite conclusions can be drawn regarding the prevalence of SV
arrhythmias in patients with PFO.
In conclusion, PFO closure does not appear to be per se an
inductor of post-procedural arrhythmias. The high prevalence of
arrhythmias detected before and after PFO closure may be related
to an increased atrial electrical vulnerability in patients with atrial
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Heart J 2012;33:2719–47.Letters to the EditorEnalapril/Carvedilol for Prevention
of Chemotherapy-Induced
Heart Failure
An End to the ProblemI read with great interest the article by Bosch et al. (1) looking at
enalapril and carvedilol for prevention of chemotherapy-induced
left ventricular systolic dysfunction (LVSD).
Clinical endpoints of the study raise a few important questions.
1. Cardinale et al. (2) randomized patients with elevated
troponin levels after high-dose chemotherapy into enalapril
and placebo treatment groups and showed that enalapril
prevented a>10% drop in LV ejection fraction (LVEF) when
compared with placebo (0% vs. 43%; p < 0.001). The
current study contradicts the Cardinale et al. (2) work because
they did not ﬁnd any interaction between the effects of ena-
lapril/carvedilol on EF and troponin elevation (p ¼ 0.59).
2. Compared with controls, patients in the intervention group
had a lower incidence of the combined event of death, heart
failure, and ﬁnal LVEF <45% (6.7% vs. 24.4%; p ¼ 0.02).
Looking closely, sepsis was a major confounding factor in
interpretation of these results because it was the major driver
